ArticleCardiology journal2025
Diagnostic potential of increased Klotho and FGF23 protein concentrations after myocardial infarction in patients with acute coronary syndrome.
Article in Cardiology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Analysis of selected cytokines, NLRP3 inflammasome and α-Klotho protein in patients with heart failure after ICD/CRT-D high-voltage intervention.Frontiers in physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKlotho is a transmembrane and secretory protein and acts as a co-receptor for fibroblast growth factor 23 (FGF23). This study aimed to analyse the concentration of Klotho and FGF23 proteins in patients with myocardial infarction (MI).
methodsThe study group comprised 129 patients diagnosed with acute coronary syndrome (ACS), who were referred for further invasive diagnostics (MI group). Blood samples were collected at 4 time points: at admission, and 6h, 24h, and between 24-48h post-admission. The criteria for the control subjects (n = 30) were no declaration of MI and ACS (non-MI group). Klotho and FGF23 concentrations in plasma were tested by ELISA at each time point.
resultsThe concentration of soluble Klotho in the MI group was increased at admission, 6h and 24 h post-admission, and then normalized at 24-48h. Klotho concentration was also significantly increased in patients with ST-segment elevation MI (STEMI) only at admission, in comparison to non-ST-segment elevation MI (NSTEMI). The concentration of FGF23 in the MI group was higher at admission, 6h and 24h post-admission, and continued to increase after 24-48 h. There was an increase in FGF23 concentration in the STEMI group at 24-48h post-admission, in comparison to NSTEMI.
conclusionsThe concentrations of Klotho and FGF23 in plasma were higher in patients with MI and changed over time. Thus, Klotho and FGF23 may be recognized as new factors in the diagnosis and/or monitoring of ACS, as well as novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.